Investors

Press Releases

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting development candidate selection for priority programs in 2022 and H1 2023 Cross species transduction for...

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose Research presented at the Alzheimer’s Association International Conference CAMBRIDGE, Mass. , Aug....

Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after...

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors

CAMBRIDGE, Mass. , July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Catherine J. Mackey , Ph.D....

Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate potential of multiple TRACER capsids to target CNS disorders, including certain diseases that may benefit...

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid improved transduction in multiple CNS regions and cell types in non-human primates with partial...

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™  AAV9- and AAV5-derived capsids Preclinical data to be presented at the ASGCT Annual Meeting to demonstrate reduction of...

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

CAMBRIDGE, Mass. , May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics , Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at the upcoming American Society of...

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy CAMBRIDGE, Mass. , March 22, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and...

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

License option agreement with Novartis for target-specific access to TRACER™  next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets Novartis agreement marks second recent major transaction to leverage Voyager’s TRACER...

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties Novartis receives target-specific access to Voyager’s novel TRACER AAV capsids for potential use with three CNS targets plus options to access...

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor...

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee

Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing...